A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Please refer to Protocol for full Inclusion criteria Participants are eligible to be included in the study only if all of the following criteria are met: • Capable of giving signed informed consent • Male or female, 18 years or older • Have a confirmed diagnosis of multiple myeloma • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 • Have been previously treated with at least 1 prior line of MM therapy including a lenalidomide-containing regimen (lenalidomide must have been administered for at least 2 consecutive cycles) and must have documented disease progression during or after their most recent therapy. • Note Participants intolerant or refractory to bortezomib at 1.3 mg/m2 dose twice weekly dosing schedule are not eligible. • Must have at least ONE aspect of measurable disease, as defined in the protocol inclusion criteria • Have undergone autologous stem cell transplant (SCT) or are considered transplant ineligible. Participants with a history of autologous SCT are eligible for study participation provided the following eligibility criteria are met: a. Autologous SCT was > 100 days prior to the first dose of study medication. b. No active bacterial, viral, or fungal infection(s) present • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] v5.0) must be < = Grade 1 at the time of enrolment, except for alopecia. • Adequate organ system functions as defined by the laboratory assessments listed in Table 2 in the inclusion criteria in Protocol. • Meet the contraception requirements of the inclusion criteria in the Protocol

Please refer to Protocol for full Exclusion criteria A participant will not be eligible for inclusion in this study if any of the following criteria are met: Prior or Concomitant Therapies • Active plasma cell leukemia at the time of screening. Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, and skin changes). • Participants after prior allogeneic SCT. NOTE: Participants who have undergone syngeneic transplant will be allowed only if no history of or no currently active graft versus host disease (GvHD). • Systemic anti-myeloma therapy (including chemotherapy and systemic steroids) or use of an investigational drug within 14 days or five half-lives (whichever is shorter) preceding the first dose of study drug; Prior treatment with a monoclonal antibody drug within 30 days of receiving the first dose of study drugs. • Plasmapheresis within 7 days prior to the first dose of study drug. • Received prior treatment with or intolerant to pomalidomide. • Received prior BCMA targeted therapy. • Intolerant to bortezomib or refractory to bortezomib (i.e., participant experienced progressive disease during treatment, or within 60 days of completing treatment, with a bortezomib-containing regimen of 1.3 mg/m2 twice weekly). Prior- or Concomitant Diseases or Conditions • Evidence of cardiovascular risk including any of the detailed criteria listed in the exclusion criteria in the protocol. • Any major surgery within the last 4 weeks. • Previous or concurrent invasive malignancy other than multiple myeloma, except; The disease must be considered medically stable for at least 2 years; or The participant must not be receiving active therapy, other than hormonal therapy for this disease. • Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment. • Evidence of active mucosal or internal bleeding. • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice. NOTE: Stable non-cirrhotic chronic liver disease (including Gilbert’s syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria). • Active infection requiring treatment. • Known human immunodeficiency virus (HIV) infection. • Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb) at Screening or within 3 months prior to first dose of study treatment). • Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing. • Intolerance or contraindications to anti-viral prophylaxis. • Presence of active renal conditions (e.g. infection, severe renal impairment • requiring dialysis or any other condition that could affect participant’s safety). • Participants with isolated proteinuria resulting from MM are eligible, provided they fulfil criteria given in Table 4 of the Protocol. • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain • Active or history of venous thromboembolism within the past 3 months. • Contraindications to or unwilling to undergo protocol-required anti-thrombotic prophylaxis • Current corneal disease except for mild punctate keratopathy (as per Section 10.9 Protocol). • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant’s safety, obtaining informed consent or compliance to the study procedures. • Pregnant or lactating female.